Vinnova's aim with the initiative is to create conditions for international competitiveness and sustainable solutions to global societal challenges. Realheart has received funding from Vinnova in two earlier rounds. This new funding will be used for additional expertise to perform blood tests with pumps in clinical use.
Heart failure is one of the most common causes of death in the world. Artificial hearts can save many lives. However, the alternative available so far has many serious blood-related complications resulting in few treated patients. An important step in the development of the next generation of artificial hearts is therefore to increase knowledge of how the pumps affect the blood, something Realheart is working on both in its own lab, in the blood lab created together with Karolinska University hospital and in collaborations with researchers around the world.
''We are very grateful for this contribution. The support will allow us to further strengthen Realheart's competitiveness and continue this important work that is of great importance to the entire heart pump industry," said Realheart's CEO Ina Laura Perkins.